Bonus Episode: Health Concerns Emerge for Saxenda, Victoza

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/61/46/d1/6146d1c8-edf0-2c1e-95a1-288cdec0e133/mza_17559741679229804596.jpg/600x600bb.jpg

Beyond the Scale: The Ozempic Effect

Drugwatch.com

7 episodes

6 days ago

First identified in the 1970s, GLP-1 medications have shaped diabetes treatments. But in recent years, the use of these drugs to help with weight loss has been revolutionary while also raising questions on safety. In Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons share in-depth research and insight from experts to reveal how GLP-1 drugs are shaping health, economics, policy and beyond.

Medicine

Health & Fitness

RSS

All content for Beyond the Scale: The Ozempic Effect is the property of Drugwatch.com and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43864068/43864068-1749653083948-da03eb69e7b.jpg

Bonus Episode: Health Concerns Emerge for Saxenda, Victoza

Beyond the Scale: The Ozempic Effect

6 minutes 11 seconds

2 months ago

Bonus Episode: Health Concerns Emerge for Saxenda, Victoza

In this special bonus episode, hosts Terry Turner and Christian Simmons revisit the topic of GLP-1 drugs to dive into emerging health concerns for Saxenda and Victoza.

New research has uncovered a potential link between liraglutide, the active ingredient in those drugs, and permanent vision loss.

To better understand the impact of this issue, Terry and Christian once again speak with attorney Danielle Gold from Weitz & Luxenberg, who is working on vision loss cases involving GLP-1s.Learn more at ⁠Drugwatch.com⁠.